CRISPR Therapeutics AG
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Samarth Kulkarni
- Full Time Employees
- 393
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Baarerstrasse 14 Zug Switzerland 6300
- IPO Date
- Oct 19, 2016
- CIK
- 0001674416
- Website
- crisprtx.com
- Similar Companies
- Business
- CRISPR Therapeutics AG (Nasdaq: CRSP) is a biotechnology company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. Founded in 2013 and headquartered in Zug, Switzerland, the company operates globally with research and development facilities in Boston and San Francisco, California, and a state-of-the-art manufacturing site in Framingham, Massachusetts. Its lead approved therapy, exagamglogene autotemcel (exa-cel, commercialized as CASGEVY in collaboration with Vertex Pharmaceuticals), is an autologous ex vivo CRISPR/Cas9 gene-edited cell therapy approved in multiple countries for eligible patients with sickle cell disease and transfusion-dependent beta-thalassemia; the company advances a broad pipeline including wholly owned and partnered programs across hemoglobinopathies such as next-generation conditioning agents and in vivo HSC editing; immuno-oncology and autoimmune therapies like CTX112 (anti-CD19 allogeneic CAR T) and other CAR T candidates targeting CD19, CD70, and glypican-3; in vivo cardiovascular programs including CTX310 (ANGPTL3), CTX320 (Lp(a)), and CTX340 (AGT for refractory hypertension); additional in vivo candidates such as CTX450 (ALAS1 for acute hepatic porphyria), CTX460 (SERPINA1 for alpha-1 antitrypsin deficiency), and undisclosed programs in rare and common diseases; regenerative medicine offerings like CTX211 and CTX213 (allogeneic gene-edited stem cell-derived therapies for type 1 diabetes); and partnered siRNA and other initiatives including SRSD107 (Factor XI for thromboembolic conditions with Sirius Therapeutics) and programs in Duchenne muscular dystrophy, myotonic dystrophy type 1, cystic fibrosis, and type 1 diabetes licensed to Vertex. In 2025, CRISPR Therapeutics expanded its portfolio through a strategic collaboration with Sirius Therapeutics, involving a $25 million cash upfront and $70 million equity investment to co-develop and commercialize novel siRNA therapies starting with SRSD107, with options for two additional programs and shared costs/profits; the company also continues global commercialization of CASGEVY, achieving regulatory approvals in nine countries and treating over 100 patients as of mid-2025 while advancing clinical milestones for CTX112, CTX310, CTX320, and others amid strong cash reserves exceeding $1.7 billion.
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript
CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
The Best Stocks to Invest $3,000 In Right Now
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It